Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas E Schlichting

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated AnalysisYoshiya Tanaka, Iain B McInnes, Peter C Taylor, et al.
RMD Open|May 17, 2018
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugsDesirée van der Heijde, Maxime Dougados, Ying-Chou Chen, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Journal of Clinical Medicine|June 20, 2019
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM TrialPeter C Taylor, Yvonne C Lee, Roy Fleischmann, et al.
The New England Journal of Medicine|March 31, 2016
Baricitinib in Patients with Refractory Rheumatoid ArthritisMark C Genovese, Joel Kremer, Omid Zamani, et al.
Annals of the Rheumatic Diseases|February 22, 2018
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studiesPeter C Taylor, Joel M Kremer, Paul Emery, et al.
EMBO Molecular Medicine|May 31, 2020
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patientsJustin Stebbing, Venkatesh Krishnan, Stephanie de Bono, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated AnalysisYoshiya Tanaka, Iain B McInnes, Peter C Taylor, et al.
RMD Open|May 17, 2018
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugsDesirée van der Heijde, Maxime Dougados, Ying-Chou Chen, et al.
Annals of the Rheumatic Diseases|November 29, 2014
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexateEdward C Keystone, Peter C Taylor, Edit Drescher, et al.
Journal of Clinical Medicine|June 20, 2019
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM TrialPeter C Taylor, Yvonne C Lee, Roy Fleischmann, et al.
The New England Journal of Medicine|March 31, 2016
Baricitinib in Patients with Refractory Rheumatoid ArthritisMark C Genovese, Joel Kremer, Omid Zamani, et al.
Annals of the Rheumatic Diseases|February 22, 2018
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studiesPeter C Taylor, Joel M Kremer, Paul Emery, et al.
EMBO Molecular Medicine|May 31, 2020
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patientsJustin Stebbing, Venkatesh Krishnan, Stephanie de Bono, et al.
Pageof 2